DAVIE, Fla. (AP) - Operation Medicine Cabinet allows residents in Broward County to turn in unused or expired prescription medication.

In return, families will receive a $5 gift card during the prescription drug "take back" event Saturday morning in Davie. Residents can also safely dispose of their personal documents, check stubs, credit card offers, receipts and other paperwork that has their personal information during the Shred-A-Thon. It's free of charge, but there's a limit of 5 boxes per person.

A Broward Sheriff's office press release says both events started in May 2008.

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Read more here:

Operation Medicine Cabinet in Broward County

WASHINGTON, July 13, 2012 /PRNewswire-iReach/ -- Science Translational Medicine, the newest journal from the American Association for the Advancement of Science (AAAS), and the Days of Molecular Medicine Global Foundation (DMM GF) announced today the launch of Days of Molecular Medicine 2012 "The Translational Science of Rare Diseases: From Rare to Care," a three-day meeting which will be held in Vienna, Austria from October 8 through October 10, 2012.

Taking place at the Palais de Lichtenstein, and featuring an international roster of academic, industrial and government scientists, headlined by Nobel Laureate Dr. Eric Kandel, the meeting will cover how new technologies are providing fresh insights into the causes of rare diseases and ways forward for developing new treatments.

Featured topics include a new targeted therapy for cystic fibrosis, exon skipping for treating muscular dystrophy, gene therapy for SCID and hemophilia, tailoring treatments with genomics, and embryonic stem cell therapy for treating retinal diseases. Joining Science Translational Medicine, AAAS and the DMM Global Foundation in launching Days of Molecular Medicine 2012 are the following co-organizers: the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Ludwig Maximilians University Munich, the Karolinska Institute, and Fondation Ipsen.

Days of Molecular Medicine 2012 is also made possible through the generous sponsorship of Boehringer Ingleheim, Inc.

"The Days of Molecular Medicine 2012 conference will discuss the many different causes of rare diseases," says Orla Smith, Managing Editor of Science Translational Medicine, "and the diverse roster of speakers will provide fresh insights into how we can develop effective new treatments."

"From cystic fibrosis to hemophilia, there are a number of diseases that, while classified as "rare", afflict a significant number of people worldwide," says Ken Chien, DMM Global Foundation Director. "With enough attention from the research community, and the application of cutting-edge technology, we can start to bring much needed relief to patients and their families. That's what DMM 2012 is all about."

"Rare diseases often come with unspeakable suffering where children are mainly affected. It is a matter of great importance to me to support every effort to share knowledge and develop new ideas, which will hopefully turn into added value for the patients, " says Dr. Josef Penninger of the IMBA. "Therefore, it is a special honor for me to host this year's Days of Molecular Medicine Meeting here in Vienna on this very topic."

For further information and to register for the meeting visit dmm.aaas.org.

About AAAS/Science Translational Medicine The American Association for the Advancement of Science (AAAS), the world's largest general scientific society, is the publisher of the journal Science (www.sciencemag.org) and the sister journals Science Translational Medicine (www.sciencetranslationalmedicine.org) and Science Signaling (www.sciencesignaling.org). The goal of Science Translational Medicine, launched in October 2009, is to promote human health by providing a forum for communicating the latest biomedical research findings from all established and emerging disciplines relevant to medicine. Despite 50 years of advances in our fundamental understanding of human biology and the emergence of powerful new technologies, the translation of this knowledge into effective new treatments and health measures has been slow. Science Translational Medicine seeks to publish articles that identify and fill the scientific knowledge gaps at the junction of basic research and medical application in order to accelerate the translation of this knowledge into new ways to prevent, diagnose and treat human disease.

About DMM Global Foundation The DMM Global Foundation is dedicated to promoting the career pathways for physician scientists. Over the past decade, the members of the Foundation have worked to initiate and establish DMM as one of the leading scientific forums to champion the importance of translational science and medicine via partnerships with leading international institutions, foundations, and scientific publishing groups. The Foundation is proud to be a co organizer and sponsor of DMM 2012.

See original here:

Science Translational Medicine and the DMM Global Foundation Announce Days of Molecular Medicine 2012 "The ...

JINCHEON, South Korea (Reuters) - South Korean athletes looking to stay in peak shape for the Lodnon Olympics are turning to Oriental rather than Western medicine to see off aches and sprains that could derail their medal chances. While some athletes remain wary of remedies that are not certified due to doping concerns, for the vast majority regular treatment has boosted fitness and the ability ...

More:

S.Koreans athletes bet on traditional medicine

(HealthDay News) -- Most anyone can buy cough medicine at the local drug store, but that doesn't mean it's harmless, especially to youngsters.

Read more from the original source:

Health Tip: Use Caution Before Giving Cough Medicine to Kids

JINCHEON, South Korea (Reuters) - South Korean athletes looking to stay in peak shape for the London Olympics are turning to Oriental rather than Western medicine to see off aches and sprains that could derail their medal chances.

While some athletes remain wary of remedies that are not certified due to doping concerns, for the vast majority regular treatment has boosted fitness and the ability to overcome injury quickly.

"I have had lots of physical therapy, which takes a long time to effect a cure, but Oriental therapy works faster. My pain halved after a day," Kim Yeon-koung from the Korean women's volleyball team told Reuters.

"I used to dislike it (acupuncture) due to the pain. Now I receive therapy regularly even if I am not hurt as my body has experienced benefits which I think boost my performance," said Kim, grimacing in pain while receiving acupuncture at a gym in Jincheon, 150 kilometres south of Seoul.

Park Jung-geu from the men's handball team said oriental medicine helped his muscles relax quickly.

"I can tell that I am getting better after being treated about three times, while physical therapy requires long, consistent treatment," he said.

Shin Joon-shik, chairman of a major traditional Korean hospital in Seoul, has treated high profile athletes such as football player Park Ji-sung, figure skating gold medallist Kim Yuna, baseball player Choo Shin-soo and golfer Paul Casey.

He said Korean traditional medicine helps to treat sprains and muscle injuries.

"Traditional Chinese medicines are more effective for chronic diseases while Korean medicines are for acute illness," he said.

Official data showed the number of oriental medicine clinics surged 32 percent to 12,292 in 2011 from 2004.

More:

South Koreans athletes bet on traditional medicine

LONDON, July 12, 2012 /PRNewswire/ -- AstraZeneca today announced that it has acquired a portfolio of neuroscience assets from Link Medicine Corporation, a privately held biopharmaceutical company based in Massachusetts, USA. Link Medicine has focused its research and development efforts in the field of autophagy, an intracellular process that clears and recycles misfolded proteins and has been developing potential new treatments for a range of neurodegenerative diseases.

AstraZeneca acquired multiple small molecule assets in clinical and preclinical stage that target the enzyme farnesyltransferase and modulate autophagy. Autophagy is an emerging area of research that can be applied to a range of neurodegenerative diseases, including Parkinson's and Alzheimer's disease. Both of these conditions are characterised by a build-up of incorrectly folded, aggregated and ultimately neurotoxic proteins.

Neuroscience is a challenging yet highly exciting area of science where there is huge unmet medical need. The agreement is the third for AstraZeneca's new neuroscience Innovative Medicines Unit, which was established earlier this year. Under this new model, AstraZeneca is continuing to invest in neuroscience discovery research and early development for small and large molecules by tapping into the best available external science.

Under the terms of the agreement, AstraZeneca will make specified upfront and milestone payments and will assume all of the programme's research and development activities. The financial terms of the deal have not been disclosed.

John F. Dee, President and CEO of Link Medicine, said: "We are delighted to have reached an agreement with AstraZeneca, who have a strong heritage in neuroscience research and development. We are confident their scientists will accelerate the development of this truly novel programme that has broad applications in neurodegenerative diseases."

Dr. Menelas Pangalos, executive vice president of Innovative Medicines, AstraZeneca, said: "AstraZeneca is committed to neuroscience drug discovery and development, and is always looking for new ways to share cost, risk and reward with other research partners. This agreement provides us with an entry into an exciting and vital piece of research into autophagy-- an area of considerable importance in neuroscience."

This innovative therapeutic approach is designed to restore the natural balance between the production and clearance of toxic protein aggregates. The long-term aim of this research is to develop disease-modifying drugs that will benefit patients with neurodegenerative diseases.

NOTES TO EDITORS

About AstraZenecaAstraZeneca (AZN)is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: http://www.astrazeneca.com

About AstraZeneca-NeuroscienceNeuroscience is a high risk, yet highly exciting area of science with huge unmet medical need. AstraZeneca is committed to neuroscience drug discovery and development, and is pioneering new ways to share cost, risk and reward with other research partners. We have created an Innovative Medicines Unit (iMed) in Neuroscience, with a team of experts based in major neuroscience hubs -- Boston (US) and Cambridge (UK)-- a network of partners focused on small and large molecule research, discovering and developing new treatments in neurology, psychiatry and neuropathic pain. Through this innovative approach, AstraZeneca is accessing the best science, expertise and capabilities-- wherever in the world they exist-- and progressing new projects flexibly and quickly from discovery through early development.

Excerpt from:

AstraZeneca Acquires Neuroscience Assets From Link Medicine

DALLAS, July 11, 2012 /PRNewswire/ --Today Baylor College of Medicine (BCM) and Gradalis, Inc. announced the signing of a Master Collaboration Agreement focused on BCM scientists' use of Gradalis' proprietary bifunctional shRNA (bi-shRNA) platform in BCM's research directed at various biological targets for therapeutic intervention. The translational medicine collaboration covers multiple BCM investigators and multiple therapeutic targets in cancer.

This collaboration will further BCM's mission of advancing human health through the integration of education, research, patient care and community service. Gradalis will benefit from the collaboration because BCM researchers will conduct early-stage research needed for proof of concept and formal pre-clinical studies, manufacturing, quality assurance and quality control, supporting assay development, regulatory submissions and clinical development.

"Agreements with commercial partners like Gradalis will help BCM accelerate the development of promising therapeutic approaches and links our strengths in discovery phase research with Gradalis' clinical development capabilities," said Adam Kuspa, Ph.D., Vice President for Research for BCM. "We look forward to a very fruitful research and development relationship."

As part of the collaboration, Gradalis will share with the scientists at BCM the company's novel bi-shRNA constructs that shut down expression of specific proteins of therapeutic interest. Gradalis will also provide BCM researchers access to its portfolio of proprietary research-enabling technologies including SuperClean DNA, reversible masking, liposomal delivery and liposomal targeting. Those bi-shRNA constructs showing promise in pre-clinical testing at BCM will be moved forward into clinical development by Gradalis.

"We look forward to entering into the collaborative development of a new line of therapeutic molecules that have not been exploited previously," said Bert W. O'Malley, M.D., Professor and Chair, BCM Department of Molecular & Cellular Biology. "To this end, the Gradalis technology, in combination with our basic discovery and pre-clinical research in molecular and cellular biology, will constitute a formidable team moving forward."

The collaboration has the potential not only to advance the interests of the two organizations but the RNA therapeutic field as a whole.

"This is truly a landmark opportunity for both organizations, and both groups stand to benefit tremendously from this relationship," said John Nemunaitis, M.D., executive medical director of the Mary Crowley Cancer Research Centers and chief medical officer and co-founder of Gradalis. "Baylor College of Medicine's pre-clinical research capabilities are best-in-class and will even further advance some of the great results we are seeing in our primary platforms, including our tumor-based personalized cancer therapeutic vaccine, FANG."

About Baylor College of Medicine

Baylor College of Medicine (www.bcm.edu) in Houston is recognized as a premier academic health science center and is known for excellence in education, research and patient care. It is the only private medical school in the greater southwest and is ranked as one of the top 25 medical schools for research in U.S. News & World Report. BCM is listed 17th among all U.S. medical schools for National Institutes of Health funding, and No. 2 in the nation in federal funding for research and development in the biological sciences at universities and colleges by the National Science Foundation. Currently, BCM trains more than 3,000 medical, graduate, nurse anesthesia, and physician assistant students, as well as residents and post-doctoral fellows. Follow Baylor College of Medicine on Facebook (http://www.facebook.com/BaylorCollegeOfMedicine) and Twitter (http://twitter.com/BCMHouston).

About Gradalis, Inc.

Read this article:

Baylor College of Medicine and Gradalis Enter Collaboration Agreement to Utilize Gradalis' Bifunctional shRNA Platform ...

Public release date: 10-Jul-2012 [ | E-mail | Share ]

Contact: Steve Majewski smajewski@acponline.org 215-351-2514 American College of Physicians

Philadelphia, July 10, 2012 -- The American College of Physicians (ACP) and the Alliance for Academic Internal Medicine (AAIM) today unveiled a high value, cost-conscious care curriculum to help train internal medicine residents about how to avoid overuse and misuse of tests and treatments that do not improve outcomes and may cause harms.

The free curriculum, available at http://www.highvaluecarecurriculum.org, is designed to engage internal medicine residents and faculty in small group activities organized around actual patient cases that require careful analysis of the benefits, harms, costs, and use of evidence-based, shared decision making. The flexible curriculum consists of ten, one hour interactive sessions that can be incorporated into the existing conference structure of a program.

"Physicians receive little specific training about identifying and eliminating wasteful diagnostic and treatment options," said Cynthia D. Smith, MD, FACP, ACP's Senior Medical Associate for Content Development and the lead author of "Teaching High-Value Cost-Conscious Care to Residents: The AAIM-ACP Curriculum," published online in Annals of Internal Medicine, ACP's flagship journal. "Residency training is an excellent time to introduce the concept of high value, cost-conscious care because the habits that residents learn during training have been shown to stay with them throughout their professional careers."

Health care expenditures are projected to reach almost 20 percent of the United States' GDP by 2020. Many economists consider this spending rate unsustainable. Up to 30 percent, or $765 billion, of health care costs were identified as potentially avoidable -- with many of these costs attributed to unnecessary services.

The committee that developed the curriculum consisted of ACP-AAIM members and staff, program directors, associate program directors, a department chair, residency faculty, and internal medicine residents.

What is High Value, Cost-Conscious Care?

High value, cost-conscious care means that a test or treatment has benefits that make its potential harms and costs worthwhile. Some expensive tests and treatments have high value because they provide high benefit and low harm. Conversely, some inexpensive tests or treatments have low value because they do not provide enough benefit to justify even their low costs and may even be harmful.

Because misuse and overuse of medical interventions that do not improve patient health contribute significantly to the unsustainable growth of health care spending, ACP launched a High Value, Cost-Conscious Care initiative in 2010 to help physicians and patients understand the benefits, harms, and costs of tests and treatment options for common clinical issues.

Read more:

New curriculum teaches internal medicine residents high value, cost-conscious care principles

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/r9t5ks/small_animal_emerg) has announced the addition of the "Small Animal Emergency and Critical Care Medicine. A Color Handbook" book to their offering.

Emergency and critical care medicine is one of the fastest growing fields of veterinary practice. Virtually every life-threatening disease can present for emergency evaluation, requiring knowledge of internal medicine, neurology, cardiology, oncology, anesthesia, and much more. Rapid and effective application of this knowledge can mean the difference between life and death for the animal.

Critical care requires the recognition of subtle changes in the clinical course of animals, and the ability to take corrective action before severe systemic disease becomes irreversible. Clinical decisions regarding seemingly small items, such as fluid therapy, antibiotics or analgesics, can have a profound impact on patient outcome

The main aim of this book - now re-issued in softcover with revised text and references (2012) - is to focus on management of the more common emergency and critical care conditions encountered in clinical practice, collated in a concise manual. There are chapters on emergencies affecting each body system, on toxicology and other environmental causes, and on critical care techniques ranging from patient monitoring, anesthesia and analgesia to fluid therapy, transfusion medicine and nutritional support, plus a chapter describing clinical skills and procedures. The text is illustrated by top-quality color photos, imaging and diagrams, and key information is highlighted in tabular form.

The authors combine experience in teaching and in clinical practice, and provide a ready resource for all those actively engaged in the field - practitioners and trainees, technicians and nurses.

Reviews of the previous edition:

A welcome addition to the reference library of any emergency clinician.

JAVMA

Extremely easy to read.. well suited for dipping into a particular chapter to get an overview of a topic.

View original post here:

Research and Markets: Small Animal Emergency and Critical Care Medicine. A Color Handbook

New research report "Sports Medicine Implants Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018" developed by GlobalData has been recently published by Market Publishers Ltd. The report suggests that the major growing segments of the overall sports medicine implants market are suture anchors, interference screws and meniscal fixation implants.London, UK (PRWEB ...

Read more:

Sports Medicine Implants Market Reviewed in New GlobalData Study Recently Published at MarketPublishers.com

NEW YORK, July 10, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Sports Medicine Implants Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

http://www.reportlinker.com/p0925660/Sports-Medicine-Implants-Market---Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

Sports Medicine Implants Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

Summary

GlobalData's new report, "Sports Medicine Implants Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018" provides key data, information and analysis on the global sports medicine implants market. The report provides market landscape, competitive landscape and market trends information on the sports medicine implants market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.

Read this article:

Sports Medicine Implants Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

Public release date: 9-Jul-2012 [ | E-mail | Share ]

Contact: Abbey Anderson aanderson@acponline.org 215-351-2656 American College of Physicians

1. Free Curriculum Aims to Educate Internal Medicine Residents About Wasteful Health Care Spending

Developed by the American College of Physicians and the Alliance for Academic Internal Medicine, the New Curriculum is Part of ACP's Ongoing High-Value, Cost-Conscious Care Initiative

Economists warn that health care spending in the United States is rising at an unsustainable rate. To slow the rate of increase, while preserving high quality care, thought leaders in academic medicine suggest that clinicians focus on using medical interventions that provide good value. This means that clinicians should weigh potential benefits against potential harms and costs before initiating an intervention. As part of an ongoing initiative to promote high-value, cost-conscious care, the American College of Physicians (ACP) and the Alliance for Academic Internal Medicine (AAIM) developed a free curriculum to help train internal medicine residents about how to avoid overuse and misuse of tests and treatments that do not improve outcomes and may cause harms. The high-value, cost-conscious care curriculum is designed to engage internal medicine residents and faculty in small group activities organized around actual patient cases that require careful analysis of the benefits, harms, costs, and use of evidence-based, shared decision making. According to the study authors, the curriculum is important because physicians receive little specific training about identifying and eliminating wasteful treatment options. Since habits that are learned during residency training have been shown to stick with physicians throughout their professional careers, it is an optimal time to prepare physicians to become good stewards of health care resources. ACP-AAIM members and staff, program directors, associate program directors, a department chair, residency faculty, and internal medicine residents collaborated to develop the curriculum. It can be accessed for free at http://www.highvaluecarecurriculum.org,

2. Evidence Reveals Little Difference in Efficacy Between Intensive Insulin Therapies, Glucose Monitoring Approaches

Advances in intensive insulin therapy and glucose monitoring are designed to improve glycemic control and quality of life while limiting adverse effects such as hypoglycemia and weight gain. Currently, there are several therapies being heavily marketed to patients, but there is little objective evidence available to guide decision making about which therapy is best for the individual patient. Researchers reviewed published studies to evaluate how intensive insulin therapy (multiple daily injections versus insulin pump) or mode of blood glucose monitoring (self-monitoring versus real-time monitoring) affects outcomes in children and adults with type 1 or 2 diabetes. The researchers found that insulin pump and multiple-daily injections have similar effects on glycemic control and the incidence of severe hypoglycemia in children and adolescents with type 1 diabetes and in adults with type 2 diabetes. However, insulin pump yielded better satisfaction with diabetes treatment in children with type 1 diabetes, and better diabetes-specific quality-of-life in adults with type 1 diabetes. As for blood-glucose monitoring, real-time monitoring achieved a lower blood glucose level compared to self-monitoring. The researchers also found that real-time glucose monitoring was associated with a lower blood glucose level compared with multiple daily injection in individuals 18 years of age or younger, but the rate of severe hypoglycemia, weight gain, and quality of life did not seem to differ between intervention groups. Patients that used a sensor-augmented pump experienced greater reduction in blood glucose compared to multiple daily injection/self-monitoring use in individuals with type 1 diabetes. The researchers conclude that based on the evidence, physicians can use patient preference to guide treatment decisions for type 1 and type 2 diabetes.

###

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

See original here:

Annals of Internal Medicine tip sheet for July 10, 2012, online issue

Readmore: Local, News, Health, Consumer, Concierge Medicine, Doctors, Insurance Companies, Members only Practice, Private Practice, Doctor Patient Relationship, Donald Vanorden, Health Care System, Healthcare, Insurence, American Academy of Private Physicians, American Medical Association

If you're one of the millions of Americans who have received a letter from your doctor informing you they're changing things up to become a "members only" practice, you know the growth of so-called "concierge medicine."

A government commission recently found the number of such red-carpet practices has increased five-fold in the last six years.

Dr. Jennifer Chilek went into private practice eight years ago at Stone Creek Family Medicine in Montgomery, Texas, but, like so many doctors across the country, she's felt the pinch as overhead goes up and reimbursements go down.

"The insurance companies have handcuffed small practices," she says.

The only way to make ends meet was to bring in more patients, which in turn means less face time with your doctor.

"The health care system is destroying the doctor-patient relationship. I couldn't have kept going the way that it was," Chilek explains.

So this year Chilek joined an estimated 3,500 private practitioners who've switched to so-called concierge or boutique medicine, which has swept the nation the last decade.

Patients pay an annual fee from $600 to $5,000, even $20,000, and insurance is not accepted.

Chilek chose a newer, more affordable model called practice membership that works with your insurance.

See more here:

What is “concierge medicine” and how does it impact you?

WALTHAM, Mass., July 9, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that it will present at the upcoming JMP Securities Healthcare Conference on Friday, July 13, 2012 at 11:30 a.m. Eastern Time. Eric Bouvier, President and CEO of the Company, will present an overview of BG Medicine. The corporate presentation will be available to the public through a webcast accessible by visiting: http://wsw.com/webcast/jmp18/bgmd/ or the "Investors" section of the Company's website at http://www.bg-medicine.com. Replays will be available for 30 days after the presentation.

About BG Medicine, Inc.

BG Medicine, Inc. (BGMD) is a life sciences company focused on the discovery, development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3TM test for use in patients with heart failure, is available in the United States and Europe. BG Medicine is also developing CardioSCORE, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http://www.bg-medicine.com and http://www.galectin-3.com.

The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352

See the article here:

BG Medicine, Inc. to Present at the JMP Securities Healthcare Conference

Seven armed youths on Sunday looted Rs 6 lakh from two wholesale medicine stores on Govind Mitra Road in daylight, sending chill down the spine of druggists.

The gang of seven split into two groups and raided the shops Ambika Agency and Kalyani Pharma in Prafulla Commercial Complex between 1pm and 1.15pm. The team of four pocketed Rs 4.5 lakh at Ambika Agency. The other looted Rs 1.5 lakh at Kalyani Pharma. Both the teams left the shops warning their owners and employees of dire consequences if they raised an alarm. The youths walked out of the two shops pulling their shutters down and fled on two-wheelers parked a little distance away. The operation lasted about 20 minutes.

According to sources, the gang members were aged between 18 and 20 years. Besides desi katta (countrymade firearms), they wielded sharp-edged traditional weapons.

Manish Kumar Makharia, the owner of Kalyani Pharma, said: Normally my shop remains closed on Sunday. But I kept the store open today because internal audit was to be carried out. I had prior appointment with a charted accountant for filing the income tax return on time.

Manish said before he or his employees could react, the operation was over. They (criminals) all were carrying arms. The money that the criminals took away from my shops locker could not be deposited in the bank because transactions are not carried out after noon on Saturdays, Manoj told the police.

Rajesh Kumar Munka, the owner of Ambika Agency, said the youths had covered their forehead with a piece of cloth (handkerchief) like professional criminals.

Woh professional ki tarah lag rahe the (They appeared to be professional criminals), he added.

Pirbhore police station house officer (SHO) Rahmat Ali said cops rushed to the spot immediately after getting information about the incident. The entire operation has been recorded in the CCTV installed in one of the two shops, he said, adding that the identity of the criminals would be ascertained with the help of the video footage.

The officer said both the shops are located at a distance from the main Ashok Rajpath. How did the criminals come to know that the shops were open today is a matter of investigation, he said.

The SHO did not rule out the involvement of people of the area in the crime. I saw one of the criminals wearing chappals (slippers) in the video footage, he added.

Continue reading here:

Heist in medicine stores

As a recent arrival to Silicon Valley and its unique culture, I?ve had the unique opportunity to consider how it contrasts with the culture of medicine, with which I?m deeply familiar. 

Continue reading here:

Medicine and Silicon Valley: Two Cultures With More In Common Than You Think

Public release date: 5-Jul-2012 [ | E-mail | Share ]

Contact: Lizzie Shannon-Little lizzie.shannonlittle@oup.com 44-186-535-3043 Oxford University Press

Oxford University Press (OUP) and the Evolution, Medicine, and Public Health Foundation are pleased to announce the launch of the open access journal Evolution, Medicine, and Public Health (EMPH).

EMPH publishes original, rigorous applications of evolutionary biology to problems in medicine and public health, and research that advances basic evolutionary biology by studying issues that arise in the medical sciences. Knowledge will flow in both directions, with emphasis on work with the potential to reduce suffering and save lives. Because evolutionary biology is a basic science that reaches across many disciplines, EMPH is open to contributions on a broad range of topics.

The President of the Foundation, Randolph Nesse, said: "Evolutionary biology is a science whose applications in medicine and public health are finally being recognized. Articles published in EMPH will bring new recognition to these applications and to studies of disease that advance basic science. The Foundation is grateful to the distinguished evolutionary biologist Professor Stephen Stearns of Yale University for agreeing to lead the journal as Editor-in Chief. He has recruited eighty-nine of the most respected scholars in their fields to serve as Associate Editors; they include, as Senior Editors, David Haig (Harvard University), Carlo Maley (University of California, San Francisco), Angela McLean (University of Oxford), Andrew Read (Pennsylvania State University), and Gregory Wray (Duke University). The Foundation looks forward to working with Oxford University Press and appreciates its willingness to make EMPH fully open access and to provide for publication by authors with limited funding. The launch of EMPH marks the coming of age of evolutionary medicine. Its content will transform our understanding of the body and disease in ways that improve human health."

Cathy Kennedy, Senior Publisher, Life Sciences, at OUP said: "We are extremely proud and excited to announce the EMPH launch. We see the new journal as a great tool to promote dialogue between the disciplines of evolutionary biology and medicine, acting as a catalyst for research that will make a serious impact on humankind. Professor Stearns has gathered together a first-class team of editors who will help to ensure that the new journal is of the very highest quality."

The first papers in Evolution, Medicine, and Public Health will be published by OUP in late 2012. The journal is now open for contributions on a broad range of topics and is designed to be of interest and accessible across a broad spectrum of biological and medical disciplines. No author's fees will apply in the first year, and arrangements are in place for on-going publication of articles by authors with limited funding. Visit the website for more information, submission guidelines, and to sign up to receive tables of contents by email or RSS: http://www.emph.oxfordjournals.org

###

For more information contact: Lizzie Shannon-Little Brand & Communications Assistant Manager Oxford University Press lizzie.shannonlittle@oup.com +44 (0)1865 353043

Notes to editors

Read more:

Oxford University Press launches Evolution, Medicine, and Public Health

(HealthDay News) -- Even over-the-counter medicine can hurt your child if given incorrectly.

Go here to read the rest:

Health Tip: Giving Your Child Medicine

By Henry Foy

MUMBAI (Reuters) - India has put in place a $5.4 billion policy to provide free medicine to its people, a decision that could change the lives of hundreds of millions, but a ban on branded drugs stands to cut Big Pharma out of the windfall.

From city hospitals to tiny rural clinics, India's public doctors will soon be able to prescribe free generic drugs to all comers, vastly expanding access to medicine in a country where public spending on health was just $4.50 per person last year.

The plan was quietly adopted last year but not publicised. Initial funding has been allocated in recent weeks, officials said.

Under the plan, doctors will be limited to a generics-only drug list and face punishment for prescribing branded medicines, a major disadvantage for pharmaceutical giants in one of the world's fastest-growing drug markets.

"Without a doubt, it is a considerable blow to an already beleaguered industry, recently the subject of several disadvantageous decisions in India," said KPMG partner Chris Stirling, who is European head of Chemicals and Pharmaceuticals.

"Pharmaceutical firms will likely rethink their emerging markets strategies carefully to take account of this development, and any similar copycat moves across other geographies," he added.

But the initiative would overhaul a system where healthcare is often a luxury and private clinics account for four times as much spending as state hospitals, despite 40 percent of the people living below the poverty line, or $1.25 a day or less.

Within five years, up to half of India's 1.2 billion people are likely to take advantage of the scheme, the government says. Others are likely to continue visiting private hospitals and clinics, where the scheme will not operate.

"The policy of the government is to promote greater and rational use of generic medicines that are of standard quality," said L.C. Goyal, additional secretary at the Ministry of Health and Family Welfare and a key proponent of the policy.

Continued here:

India to give free medicine to hundreds of millions

NEW YORK, July 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022

http://www.reportlinker.com/p0923283/Nuclear-Medicine-Imaging-Devices-Global-Market-Prospects-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

Report Details

Our latest pharma report -Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022- offers a comprehensive view of the global nuclear medicine imaging systems market. The report analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses, revealing areas that will experience growth and present new business opportunities. Visiongain analyses predict the global value of the nuclear medicine imaging systems market in 2011 to be worth $1.5bn. Growth in this market will be driven by new technology and varied uses of the technology.

Despite experiencing a decline in sales volume and reduced demand in the aftermath of the global economic recession, the nuclear medicine market recovered well, and has seen strong growth in recent years. Much of this growth has been linked to the advent of hybrid units, such as positron emission tomography/computed tomography (PET/CT) scans, where both anatomical and functional images can be captured. For example, the combination of Positron Emission Tomography (PET) with other imaging modalities, such as MRI (Magnetic Resonance Imaging) has allowed for the imaging of cartilage damage, previously thought unreliable.

Nuclear Medicine Imaging Devices: Market Global Market Prospects 2012-2022report forecasts the size and value of leading national/regional markets including the US, Europe, Japan, India and China. For each of these, visiongain identifies prevailing trends and strategies that will steer this diagnostic technology over the forecast period. Developed nuclear medicine markets such as the US and UK are highly saturated and the focus is likely to be towards upgrading stand-alone PET and SPECT system with fully integrated hybrid units, that offer a high level of anatomical and functional detail. Emerging countries such asChinaandIndiawill offer more opportunity, due a lack of nuclear medicine facilities and technologies, and increased healthcare spending. It has been predicted that healthcare investment in these countries is expected to double in the next seven years.

How will the nuclear medicine imaging systems market develop this decade? Which regions offer the most significant growth opportunities between 2012 and 2022? Which of the nuclear medicine based imaging devices are growing most strongly? Who are the leading companies in the nuclear medicine imaging systems market? What are some promising technological developments in the market?

Visiongain answers these critical questions and many more through the in-depth analyses that are presented in this report.

Why you should buyNuclear Medicine Imaging Devices: Global Market Prospects 2012-2022

Go here to read the rest:

Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022